Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multivirus-specific T Cells for Refractory CMV/EBV Post-HSCT
NCT06075927Phase 2Unknown
- Sponsor
- Peking University People's Hospital
- Start
- Nov 2023
- Primary completion
- Jul 2025
- Modality
- Cell Therapies
01
Overview
Phase 2, open-label, single-arm trial of virus-specific T cells in cytomegalovirus infection (CMV) and Epstein-Barr virus infection, sponsored by Peking University People's Hospital. Primary endpoints: Assessment of safety and toxicity outcomes at 56 days and Assessment of antiviral efficacy at 56 days. Status: unknown.
02
Drugs
virus-specific T cells
03
Conditions
cytomegalovirus infection (CMV)Epstein-Barr virus infection
Beyond the preview
Go deeper on NCT06075927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06075927.